Get the Stockscreener App
242.51
0.26%
0.62
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $242.51, with a volume of 361.37K.
It is up +0.26% in the last 24 hours and up +2.62% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$241.89
Open:
$243
24h Volume:
361.37K
Relative Volume:
0.34
Market Cap:
$26.77B
Revenue:
$11.28B
Net Income/Loss:
$1.07B
P/E Ratio:
26.75
EPS:
9.0657
Net Cash Flow:
$1.33B
1W Performance:
+3.24%
1M Performance:
+2.62%
6M Performance:
+23.56%
1Y Performance:
+33.12%
1-Day Range:
$241.12
$244.22
1-Week Range:
$223.50
$246.00
52-Week Range:
$171.18
$248.84
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
242.51 | 26.77B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
680.76 | 251.71B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
232.29 | 163.30B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
405.38 | 58.43B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
176.09 | 49.64B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
275.08 | 45.28B | 16.63B | 1.39B | 2.12B | 8.0674 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term - Zacks Investment Research
DGX Q3 Earnings & Revenues Beat, '26 View Raised, Stock Down in Pre-Market - Zacks Investment Research
Quest Diagnostics (DGX) Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research
Quest Diagnostics (DGX): Is Rapid Test Growth Translating Into Better Customer Economics? - Yahoo Finance
Waters, Quest Diagnostics Collaborate to Expand Access to At-Home HPV Screening for Cervical Cancer - marketscreener.com
Quest Diagnostics Inc expected to post earnings of $2.86 a shareEarnings Preview - TradingView
Quest Diagnostics, Waters plan at-home HPV access in 2027 | DGX Stock News - Stock Titan
A new at-home HPV test kit is going national through Quest Diagnostics - Fast Company
Quest Diagnostics Slides as Investors Weigh Medicare Lab Payment Cut Risk - Quiver Quantitative
UBS Raises Quest Diagnostics Price Target to $250 From $245, Maintains Neutral Rating - marketscreener.com
Current guidelines may miss half of people with a hormone disorder tied to high blood pressure. - Stock Titan
DGX4807226 Bond Profile: Coupon and Redemption - TradingView
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors - MarketWatch
Quest Diagnostics Incorporated (DGX) Options ChainYahoo Finance - Yahoo! Finance Canada
Quest Diagnostics Incorporated (DGX) Options ChainYahoo Finance - Yahoo! Finance Canada
Quest Diagnostics Incorporated (DGX) Options ChainYahoo Finance - Yahoo! Finance Canada
Quest Diagnostics Incorporated (DGX) Stock forecasts - Yahoo Finance UK
Quest Diagnostics shares may shift 4.4% on Oct. 22 earnings - Investing.com
Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo Finance
Quest Continues to Enjoy a Narrow Moat Thanks to Its Status as Low-Cost Producer - Morningstar
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo! Finance Canada
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings - Zacks Investment Research
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings - TradingView
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings - Yahoo Finance
Quest Diagnostics (NYSE:DGX): A Dividend Quality Pick for Income Investors - ChartMill
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Leerink Partners Adjusts Quest Diagnostics Price Target to $265 From $254 - www.marketscreener.com
Quest Diagnostics Incorporated (DGX) options chain - Yahoo Finance UK
Quest Diagnostics (DGX) Announces Executive Leadership Transitio - GuruFocus
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catherine T. Doherty to Transition to EVP at Quest Diagnostics, Retirement Set for July 2027 - TradingView
Barclays Adjusts Price Target on Quest Diagnostics to $260 From $250, Keeps Overweight Rating - marketscreener.com
Evercore ISI Adjusts Price Target on Quest Diagnostics to $235 From $240, Keeps In Line Rating - www.marketscreener.com
Quest Diagnostics Inc's Dividend Analysis - Yahoo Finance
Quest Diagnostics (NYSE:DGX) Rides Steady Testing Demand - Kalkine Media
Quest Diagnostics’ Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus - Zacks Investment Research
DGX5874579 Bond Profile: Coupon and Redemption - TradingView
Three Days Left To Buy Quest Diagnostics Incorporated (NYSE:DGX) Before The Ex-Dividend Date - Moomoo
Quest Diagnostics (NYSE:DGX) Breakout Setup Backed by Technical Rating 7 and Setup Rating 8 - ChartMill
Quest Diagnostics (DGX) Highlights Haystack MRD Test Accuracy in Colorectal Cancer Trials - GuruFocus
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? - TradingView
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? - Yahoo Finance
Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments - GlobeNewswire Inc.
Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch - Yahoo Finance
Quest Diagnostics shows growth potential despite Medicare uncertainties, driven by testing demand and acquisitions. - Pluang
Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds - Seeking Alpha
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quest Diagnostics Inc Stock (DGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Davis J. E. | Officer |
Sep 01 '26 |
Proposed Sale |
242.72 |
10,000 |
2,427,200 |
0 |
| PREVOZNIK MICHAEL E | SVP & General Counsel |
Aug 28 '26 |
Sale |
243.11 |
22,677 |
5,513,083 |
37,557 |
| PREVOZNIK MICHAEL E | SVP & General Counsel |
Aug 28 '26 |
Option Exercise |
112.17 |
22,677 |
2,543,679 |
60,234 |
| PREVOZNIK MICHAEL E | Officer |
Aug 28 '26 |
Proposed Sale |
243.11 |
22,677 |
5,513,082 |
0 |
| DELANEY MARK E | Officer |
Jul 28 '26 |
Proposed Sale |
235.18 |
1,600 |
376,288 |
0 |
| DELANEY MARK E | SVP & Chief Commercial Officer |
Jul 28 '26 |
Sale |
235.18 |
1,600 |
376,288 |
10,335 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions |
Jun 04 '26 |
Option Exercise |
124.22 |
8,147 |
1,012,000 |
21,657 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions |
Jun 04 '26 |
Sale |
200.00 |
8,147 |
1,629,400 |
13,510 |
| KUPPUSAMY KARTHIK | Officer |
Jun 04 '26 |
Proposed Sale |
200.00 |
8,147 |
1,629,400 |
0 |
| Davis J. E. | CEO and President |
Jun 01 '26 |
Sale |
194.14 |
10,000 |
1,941,400 |
132,423 |
0.09%
3.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):